Research begun by microbiology professor David Bedwell, Ph.D., identifying nonsense mutations in Cystic Fibrosis patients, has led to a collaboration between UAB and Southern Research with the goal of developing novel drugs for Cystic Fibrosis (CF) patients with rare genetic mutations.

Research begun by microbiology professor David Bedwell, Ph.D., identifying nonsense mutations in Cystic Fibrosis patients, has led to a collaboration between UAB and Southern Research with the goal of developing novel drugs for Cystic Fibrosis (CF) patients with rare genetic mutations.

The Cystic Fibrosis Foundation's nonprofit drug discovery and development affiliate, Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), has awarded $7.5 million to fund this project.

Cystic Fibrosis Foundation Therapeutics Announces $7.5 Million Award to Discover New Therapies for Nonsense Mutations

Southern Research Receives $7.5 Million Award to Discover New Therapies for Cystic Fibrosis Patients with Rare Mutations

Turning nonsense into good sense